Molecular classification of breast cancer into subtypes based on expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have provided therapeutic options that have improved clinical outcome. This evidence concerns the gene ERBB2 and breast cancer.